Francesco International Predicts Lipitor Will Gain Nonprescription (OTC) Status in 2016 as the Internet Enhances the Safety of Many Drugs Used in Chronic Therapy Care

Share Article

The use of the internet can dramatically increase the OTC possibilities of many drugs currently requiring a prescription. Francesco International has released a major report on this increasingly important subject entitled "The Major Expansion of Rx-to-OTC Switch by 2016: OTC-E™ Drugs Will Lead the Way."

The ability to create a "closed feedback loop" will allow the approval of more prescription drugs to over-the-counter status, starting with Lipitor in 2016.

There are positive, sweeping changes occurring in the ability of companies to convert prescription drugs to OTC status. For example, the recent consolidation of Rx-to-OTC switch drug manufacturers has created better funded switch opportunities as well as larger drug portfolios to draw upon.

Perhaps more importantly, game-changing advances made in healthcare technology, especially via the use of the Internet will create the first ever "closed feedback loop" communication, which can dramatically improve the safety environment for drugs and allow consumers and non-physician healthcare professionals to better monitor health outcomes and make changes. The entire safety profile as an OTC will be greatly enhanced, allowing some chronic therapy drug, such as Lipitor, to become OTC.

Francesco International LLC, a cutting-edge pharmaceutical think-tank and healthcare consultancy based in New York, predicts this change in the industry. They have published a breakthrough 100-page report regarding the issue, “The Major Global Expansion of Rx-to-OTC Switch by 2016: OTC-E Drugs Will Lead the Way." (

Most important, this new group of drugs will be used primarily for chronic therapy treatment and thereby lowering health care costs. Amongst others, therapy areas impacted will be hypertension, dermatology, lipid-lowering, osteoporosis, arthritis and incontinence.

“This is a breakthrough report that focuses on the changing dynamics of Rx-to-OTC switch between now and 2016 and beyond, well into the future,” says Francesco, the principal author of the report.
The report is for companies interested in exploring the promising opportunities of Rx-to-OTC switch that will surface in the next few years. In addition, the report identifies key therapy and product areas for switches that can benefit from a combination of the drug plus the use of the exciting new technology.

For more information on “The Major Expansion of the Rx-to-OTC Switch by 2016: OTC-E™ Drugs Will Lead the Way" visit

About Francesco International LLC

Francesco International Inc. has been actively involved in pharmaceutical lifecycle management with a focus on Rx-to-OTC switch for over twenty years, consulting for numerous pharmaceutical companies worldwide. The firm published the newsletter, “SWITCH,” as well as SWITCH Market Impact studies. It has its own proprietary planning model “Max the Molecule” for assessing opportunities. CEO Steven Francesco has authored over fifty articles and essays on the pharmaceutical industry and is a recognized expert on product life cycle issues. He has been on the board of several companies.

Steven Francesco, CEO
Francesco International LLC

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steve Francesco
Francesco International
+1 (973) 985-0589
Email >